• Title of article

    Cancer incidence estimation at a district level without a national registry: A validation study for 24 cancer sites using French health insurance and registry data

  • Author/Authors

    Uhry، نويسنده , , Zoé and Remontet، نويسنده , , Laurent and Colonna، نويسنده , , Marc and Belot، نويسنده , , Aurélien and Grosclaude، نويسنده , , Pascale and Mitton، نويسنده , , Nicolas and Delacour-Billon، نويسنده , , Solenne and Gentil، نويسنده , , Julie and Boussac-Zarebska، نويسنده , , Marjorie and Bossard، نويسنده , , Nadine and Danzon، نويسنده , , Arlette and Altana، نويسنده , , Michelle and Frete، نويسنده , , François and Weill، نويسنده , , Alain and Rogel، نويسنده , , Agnès، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2013
  • Pages
    16
  • From page
    99
  • To page
    114
  • Abstract
    Background: District-level cancer incidence estimation is an important issue in countries without a national cancer registry. This study aims to both evaluate the validity of district-level estimations in France for 24 cancer sites, using health insurance data (ALD demands – Affection de Longue Durée) and to provide estimations when considered valid. Incidence is estimated at a district-level by applying the ratio between the number of first ALD demands and incident cases (ALD/I ratio), observed in those districts with cancer registries, to the number of first ALD demands available in all districts. These district-level estimations are valid if the ratio does not vary greatly across the districts or if variations remain moderate compared with variations in incidence rates. Methods: Validation was performed in the districts covered by cancer registries over the period 2000–2005. The district variability of the ALD/I ratio was studied, adjusted for age (mixed-effects Poisson model), and compared with the district variability in incidence rate. The epidemiological context is also considered in addition to statistical analyses. Results: District-level estimation using the ALD/I ratio was considered valid for eight cancer sites out of the 24 studied (lip–oral cavity–pharynx, oesophagus, stomach, colon–rectum, lung, breast, ovary and testis) and incidence maps were provided for these cancer sites. Conclusion: Estimating cancer incidence at a sub-national level remains a difficult task without a national registry and there are few studies on this topic. Our validation approach may be applied in other countries, using health insurance or hospital discharge data as correlate of incidence.
  • Keywords
    cancer , Incidence , Health insurance data , registries , statistical modelling
  • Journal title
    Cancer Epidemiology
  • Serial Year
    2013
  • Journal title
    Cancer Epidemiology
  • Record number

    1766012